

DAFTAR PUSTAKA

- Alatas H, Tambunan T, Trihono P, Pardede SO. Konsensus Tatalaksana Sindrom Nefrotik Idiopatik pada Anak. Jakarta. Indonesia:2005
- Aggarwal N, Appel GB. Focal Segmental Glomerulosclerosis. In: Greenberg A, ed. Primer on Kidney Disease. 5th ed., Philadelphia: WB: Saunder;2009: 165-70.
- Appel GB. Glomerular Disorders and Nephrotic Syndromes. In: Goldman L, Ausiello D, eds. Cecil Medicine. 23rd ed. Philadelphia, Pa: Saunders Elxevier.2007: chap 122.
- Barison L, dkk. A Proposed Taxonomy for the Podocytopathies: A Reassessment of the Primary Nephrotic Diseases. Clinical Journal of the American Society of Nephrology 2: 529-542, 2007
- Borges FF, Shiraichi L, da Silva MP, Nishimoto EI, Nogueira PC. Is focal segmental glomerulosclerosis increasing in patients with nephrotic syndrome? Pediatric Nephrology 2007; 22(9):1309-13.
- Bhimma Rajendra. *Idiopathic Steroid Resistant Nephrotic Syndrome In Children*. Journal Nephrology Therapeutic. 2014.
- D'Agati V. Focal Segmental Glomerulosclerosis. In: D'Agati V, Jannette JC, Siva FS, eds. Atlas of Non-Tumor Pathology: Nonneoplastic Kidney Disease. Silver Springer, Md: American Registry of Pathology Brees, 2005: 125-59.
- Eddy Alison A, Jordan M Symons. *Nephrotic Syndrome In Childhood*. The Lancet volume 362, pages 629-639. 2003.

M et al. (2011). Molecular and Genetic Basis of Inherited Nephrotic Syndrome. International Journal of Nephrology



Ishimoto D, dkk. Minimal Change Disease: A CD80 podocytopathy?. *Semin Nephrol* 31:320-325. Elsevier 2011.

Kiffel J, Rahimzada Y, Trachtman H. Focal Segmental Glomerulosclerosis and Chronic Kidney Disease in Pediatric Patients. *Adv Chronic Kidney Dis.* 2011;18(718):332-338.

Kanemoto Katsuyoshi, Ito Hidekazu, Anzai Michiko, Matsumura Chieko, Kurayama Hideaki et.al. Clinical significance of IgM and C1q deposition in the mesangium in pediatric idiopathic nephritic syndrome. *JNephrology.* 2013; 26(02):306-14. Available from: www.jnephrol.com/article/clinical-sign

Kitiyakana C, Eggers P, Kopp JB. 21 year trend in ESRD due to FSGS in The United States. *Am J Kidney Dis.* 2004;44: 815-25.

Kumar J, Gulati S, Sharma AP, Sharma RK, Gupta RK. Histopathological spectrum of childhood nephrotic syndrome in Indian children. *Pediatr Nephrol* 2003; 18: 657-660.

Kumar Vinay, Cotran Ranzi S., Robbins Stanley L. *Buku Ajar Patologi Volume 2.* Edisi 7. Jakarta: Penerbit Buku Kedokteran EGC; 2010

Keddis Mira T, Bernard M Karnath et al. *The Nephrotic Syndrome.* University of Texas Medical Branch, Galveston, TX. 2007

Matar RB, Valentini RP, Smoyer WE. Primary podocytopathies. Dalam: Kher KK, Schnaper HW, Greenbaum LA (ed). *Clinical Pediatric Nephrology.* Edisi 3. Boston: CRC Press 2017. h.307-9.

Biochemical disorders in human disease. 2nd ed. London: Churchill
td:1976: 211



Mubarak M et al. (2009). Histopathological Spectrum of Childhood Nephrotic Syndrome in Pakistan. *Clin Exp Nephrol.* 13(6): 589-93.

Nachman Patrick H, Jannette Charles J., Falk Ronald J. Primary Glomerular Disease. In: Brenner, Barry M, editors. *The Kidney 8th Edition* volume 1. Philadelphia: Saunders Elsevier; 2008. p. 1000-03, 1019-28

Niaudet P. Steroid Sensitive Nephrotic Syndrome. Dalam: Avner ED, Harmon WE, Niaudet P, penyunting. *Pediatric nephrology.* Edisi ke-5. Philadelphia: Lippincott William & Wilkins; 2004. hlm. 543–73.

Noer, MS et al. *Kompendium Nefrologi Anak.* Ikatan Dokter Anak Indonesia. Jakarta.2011.

Novina, Dida Akhmad Gurnida, Nanan Sekarwana. Korelasi Kadar Albumin Serum dengan Persentase Edema pada Anak Penderita Sindrom Nefrotik dalam Serangan. *Majalah Kedokteran Bandung* Vol.47, No.1 (2015)

Park Se Jin, Jae li Shin. *Complications of Nephrotic Syndrome.* Korean Journal Pediatric. 2011.

Rachmadi Dedi. *Aspek Genetik Sindrom Nefrotik.* Bagian Ilmu Kesehatan Anak, Fakultas Kedokteran Universitas Padjajaran. 2010.

Seif Elham Ibrahim, Eman Abdel-Salam Ibrahim et al. *Histological patterns of idiopathic steroid resistant nephrotic syndrome in Egyptian children: A single centre study.* *Nephropathology Journal.* 2013.

Situmorang D, Sekarwana N, Fadlyana E. Risk factor of frequent relapse in pediatric nephrotic syndrome. *American Journal of Medical and Biological Research,* vol. 4, no. 1, 2016: 10-12



Sudiharjo W, Prasetyo RV, Umijati S. Clinical profile of children with steroid-sensitive idiopathic nephrotic syndrome relapsing in the first year at dr.Soetomo hospital, Surabaya. *Folia Medica Indonesiana* Vol. 48 No.4, 2012 :180-185

Swarnali M.J et al. (2016). Focal Segmental Glomerulosclerosis as the Leading Cause of Idiopathic Nephrotic Syndrome: a Different Spectrum Revealed by Mandatory Renal Biopsy in all Patients. *Sri Lanka Journal of Child Health*. 45(2):76-83

Syarifuddin Rauf. *Catatan Kuliah Nefrologi Anak*. Bagian Ilmu Kesehatan Anak Fakultas Kedokteran Universitas Hasanuddin. 2009.

Talaat, HS. *Treatment Strategies for Childhood Steroid Resistant Nephrotic Syndrome*. *British Journal of Medicine & Medical Research* 3(4): 1074-1086. 2013.

Trihono Partini P, Husein Alatas et al. *Konsensus Tata Laksana Sindrom Nefrotik Idiopatik Pada Anak*. Unit Kerja Koordinasi Nefrologi IDAI. 2012.

Vande Walle JG, Donckerwolcke RA, Koomans HA. Pathophysiology of edema formation in children with nephrotic syndrome not due to minimal change disease. *J Am Soc Nephrol*. 1999;10:323–31

Wisata L, et al. Perbedaan Aspek Klinis Sindrom Nefrotik Resisten Steroid dan Sensitif Steroid pada Anak *Majalah Kedokteran Indonesia*, Volume: 60, Nomor:12. 2010.

Wila Wlrya IG. Sindrom Nefrotik. Dalam Alatas H, Tambunan T, Trihono P, Pardede SO. *Buku Ajar Nefrologi Anak*. Edisi Kedua. Jakarta: Balai Penerbit FKUI; 2009. h.381-91, 410-22.



Yoseph A. (2014). Distribusi Gejala Klinik Penderita Sindrom Nefrotik Berdasarkan Gambaran Histopatologi di RSUP Dr. Kariadi Tahun 2008-2013. Skripsi. Semarang: Universitas Diponegoro.



Lampiran 1.



KEMENTERIAN RISET, TEKNOLOGI DAN PENDIDIKAN TINGGI
UNIVERSITAS HASANUDDIN
FAKULTAS KEDOKTERAN
RSPTN UNIVERSITAS HASANUDDIN
RSUP Dr. WAHIDIN SUDIROHUSODO MAKASSAR
KOMITE ETIK PENELITIAN KESEHATAN



Sekretariat : Lantai 3 Gedung Laboratorium Terpadu
 JL.PERINTIS KEMERDEKAAN KAMPUS TAMALANREA KM.10 MAKASSAR 90245.
 Contact Person: dr. Agussalim Bukhari, MMed, PhD, SpGK TELP. 081241850858, 0411 5780103, Fax : 0411-581431

REKOMENDASI PERSETUJUAN ETIK

Nomor : 393 / H4.8.4.5.31 / PP36-KOMETIK / 2018

Tanggal: 25 Mei 2018

Dengan ini Menyatakan bahwa Protokol dan Dokumen yang Berhubungan Dengan Protokol berikut ini telah mendapatkan Persetujuan Etik :

No Protokol	UH18050300	No Sponsor Protokol	
Peneliti Utama	dr. Muh Alfian Jafar	Sponsor	Pribadi
Judul Peneliti	Perbandingan Aspek Klinis dan Laboratorium Sindrom Nefrotik Kelainan Minimal dan Bukan Kelainan Minimal Pada Anak		
No Versi Protokol	1	Tanggal Versi	14 Mei 2018
No Versi PSP		Tanggal Versi	
Tempat Penelitian	RSUP dr. Wahidin Sudirohusodo dan RSPTN Unhas di Makassar		
Jenis Review	<input type="checkbox"/> Exempted <input checked="" type="checkbox"/> Expedited <input type="checkbox"/> Fullboard Tanggal	Masa Berlaku 25 Mei 2018 sampai 25 Mei 2019	Frekuensi review lanjutan
Ketua Komisi Etik Penelitian	Nama Prof.Dr.dr. Suryani As'ad, M.Sc.,Sp.GK (K)	Tanda tangan 	Tanggal
Sekretaris Komisi Etik Penelitian	Nama dr. Agussalim Bukhari, M.Med.,Ph.D.,Sp.GK (K)	Tanda tangan 	Tanggal

Kewajiban Peneliti Utama:

- Menyerahkan Amandemen Protokol untuk persetujuan sebelum di implementasikan
- Menyerahkan Laporan SAE ke Komisi Etik dalam 24 Jam dan dilengkapi dalam 7 hari dan Laporan SUSAR dalam 72 Jam setelah Peneliti Utama menerima laporan
- Menyerahkan Laporan Kemajuan (progress report) setiap 6 bulan untuk penelitian resiko tinggi dan setiap setahun untuk penelitian resiko rendah
- Menyerahkan laporan akhir setelah Penelitian berakhir
- Melaporkan penyimpangan dari prokol yang disetujui (protocol deviation / violation)
- Mematuhi semua peraturan yang ditentukan



Lampiran 2.



Nomor : LB.02.01/2.21/6477/2018
Hal : Izin Penelitian

07 Agustus 2018

Yth. Inst. Rekam Medik

Dengan ini kami hadapkan peneliti :

Nama : dr. Muh Alfian Jafar
NIM : C110214110
Prog. Studi : Dokter Spesialis Anak
Fakultas : Kedokteran
Universitas : Hasanuddin Makassar
No. HP : 081342990580

Yang bersangkutan akan melakukan penelitian dengan judul "*Perhubungan Aspek Klinis dan Laboratorium Sindrom Nefrotik Kelainan Minimal dan Bukan Kelainan Minimal pada Anak Tahun 2016 s.d 2018*" sesuai dengan permohonan peneliti dari Ketua Dep. I.K. Anak FK Unhas, dengan nomor 7858/UN4.6.8/PL.00.00/2018, tertanggal 05 Juni 2018. Penelitian ini berlangsung selama bulan Agustus s.d Oktober 2018, dengan catatan selama penelitian berlangsung peneliti :

1. Wajib memakai ID Card selama melakukan penelitian di RSUP. Dr. Wahidin Sudirohusodo
2. Wajib mematuhi peraturan dan tata tertib yang berlaku di RSUP. Dr. Wahidin Sudirohusodo
3. Tidak mengganggu proses pelayanan terhadap pasien.
4. Tidak diperkenankan membawa status pasien keluar dari Ruang Rekam Medik
5. Tidak diperbolehkan mengambil gambar pasien dan identitas pasien harus dirahasiakan

Demikian Surat ini dibuat untuk di pergunakan sebagaimana mestinya



Catatan :

1. Pelaksanaan sesuai ketentuan
2. Kerahasiaan data terjaga
3. Hasil penelitian diserahkan ke Bag. Diklit



Optimization Software:
www.balesio.com

Lampiran 3.

8/8/2018

Surat Pernyataan Muh.Alfian Jafar

 RUMAH SAKIT UNIVERSITAS HASANUDDIN	SURAT IZIN PENELITIAN	
	Nomor: 4954/UN4.26.1.2/PL.02/2018	Tanggal 09 Agustus 2018
FORMULIR 2 BIDANG PENDIDIKAN DAN PENELITIAN	Kepada Yth Kepala Instalasi Rekam Medis	
<p>Dengan hormat,</p> <p>Dengan ini menerangkan bahwa peneliti/ mahasiswa berikut ini:</p> <p>Nama : Muh.Alfian Jafar</p> <p>NIM / NIP : C11014110</p> <p>Institusi : Ilmu Kesehatan Anak, Fakultas Kedokteran, Universitas Hasanuddin</p> <p>Kode peneliti : 180809_2</p> <p>Akan melakukan pengambilan data/ analisa bahan hayati:</p> <p>Terhitung : 09 Agustus 2018 s/d 31 Agustus 2018</p> <p>Jumlah Subjek/Sample : 60</p> <p>Jenis Data : Rekam Medis pasien Sindrom Nefrotik pada Anak</p> <p>Untuk penelitian dengan judul:</p> <p>"Perbandingan Aspek Klinis Dan Laboratorium Sindrom Nefrotik Kelainan Minimal dan Bukan Kelainan Minimal Pada Anak"</p> <p>Harap dilakukan pembimbingan dan pendampingan seperlunya.</p> <p>Kepala Bidang Penelitian</p> <p> dr. Firdaus, PhD NIP.197712312002121002</p> <p><i>Catatan: Lembaran ini disiapkan oleh Bidang Penelitian dan Inovasi</i></p>		

http://rs.unhas.ac.id/penelitian/peneliti/surat_izin_penelitian/596

1/1



Lampiran 5

Hasil Analisis statistik distribusi jenis kelamin pada SNKM dan SNBKM

Cross tabulation

			Biopsi		Total
			kelainan minimal	bukan kelainan minimal	
JK laki-laki	Count	7	15	22	
	Expected Count	6.1	15.9	22.0	
	% within Biopsi	70.0%	57.7%	61.1%	
perempuan	Count	3	11	14	
	Expected Count	3.9	10.1	14.0	
	% within Biopsi	30.0%	42.3%	38.9%	
Total	Count	10	26	36	
	Expected Count	10.0	26.0	36.0	
	% within Biopsi	100.0%	100.0%	100.0%	

Chi-Square Tests

	Value	df	Asymptotic Significance (2-sided)	Exact Sig. (2-sided)	Exact Sig. (1-sided)
Pearson Chi-Square	.460 ^a	1	.497		
Continuity Correction ^b	.088	1	.767		
Likelihood Ratio	.471	1	.493		
Fisher's Exact Test				.706	.389
N of Valid Cases	36				

a. 1 cells (25.0%) have expected count less than 5. The minimum expected count is 3.89.

^b Computed only for a 2x2 table



Risk Estimate

	Value	95% Confidence Interval	
		Lower	Upper
Odds Ratio for JK (laki-laki / perempuan)	1.711	.359	8.145
For cohort Biopsi = kelainan minimal	1.485	.459	4.807
For cohort Biopsi = bukan kelainan minimal	.868	.584	1.289
N of Valid Cases	36		



Lampiran 6

Hasil Analisa statistik nilai rerata umur pada SNKM dan SNBKM

Mann-Whitney test

Ranks

	Biopsi	N	Mean Rank	Sum of Ranks
Usia	kelainan minimal	10	19.45	194.50
	bukan kelainan minimal	26	18.13	471.50
	Total	36		

Test Statistics^a

	Usia
Mann-Whitney U	120.500
Wilcoxon W	471.500
Z	-.338
Asymp. Sig. (2-tailed)	.736
Exact Sig. [2*(1-tailed Sig.)]	.741 ^b

a. Grouping Variable: Biopsi

b. Not corrected for ties.



Lampiran 7

Hasil analisis statistik distribusi hipertensi pada SNKM dan SNBKM

Hipertensi * Biopsi Crosstabulation

		Biopsi		Total
		kelainan minimal	bukan kelainan minimal	
Hipertensi ya	Count	1	15	16
	Expected Count	4.4	11.6	16.0
	% within Biopsi	10.0%	57.7%	44.4%
tidak	Count	9	11	20
	Expected Count	5.6	14.4	20.0
	% within Biopsi	90.0%	42.3%	55.6%
Total	Count	10	26	36
	Expected Count	10.0	26.0	36.0
	% within Biopsi	100.0%	100.0%	100.0%

Chi-Square Tests

	Value	df	Asymptotic Significance (2-sided)	Exact Sig. (2-sided)	Exact Sig. (1-sided)
Pearson Chi-Square	6.653 ^a	1	.010		
Continuity Correction ^b	4.862	1	.027		
Likelihood Ratio	7.534	1	.006		
Fisher's Exact Test				.022	.011
N of Valid Cases	36				

a. 1 cells (25.0%) have expected count less than 5. The minimum expected count is 4.44.

b. Computed only for a 2x2 table



Risk Estimate

	Value	95% Confidence Interval	
		Lower	Upper
Odds Ratio for Hipertensi (ya / tidak)	12.273	1.350	111.609
For cohort Biopsi = bukan kelainan minimal	1.705	1.124	2.584
For cohort Biopsi = kelainan minimal	.139	.020	.985
N of Valid Cases	36		



Lampiran 8

Hasil analisis statistik distribusi proteinuria pada SNKM dan SNBKM

Proteinuria * Biopsi Crosstabulation

		Biopsi		Total
		kelainan minimal	bukan kelainan minimal	
Proteinuria massif	Count	9	24	33
	Expected Count	9.2	23.8	33.0
	% of Total	25.0%	66.7%	91.7%
tidak	Count	1	2	3
	Expected Count	.8	2.2	3.0
	% of Total	2.8%	5.6%	8.3%
Total	Count	10	26	36
	Expected Count	10.0	26.0	36.0
	% of Total	27.8%	72.2%	100.0%

Chi-Square Tests

	Value	df	Asymptotic Significance (2-sided)	Exact Sig. (2-sided)	Exact Sig. (1-sided)
Pearson Chi-Square	.050 ^a	1	.822		
Continuity Correction ^b	.000	1	1.000		
Likelihood Ratio	.049	1	.825		
Fisher's Exact Test				1.000	.636
Linear-by-Linear Association	.049	1	.825		
N of Valid Cases	36				

a. 2 cells (50.0%) have expected count less than 5. The minimum expected count is .83.

b. Computed only for a 2x2 table



Risk Estimate

	Value	95% Confidence Interval	
		Lower	Upper
Odds Ratio for Proteinuria (massif / tidak)	1.333	.107	16.567
For cohort Biopsi = bukan kelainan minimal	1.091	.477	2.494
For cohort Biopsi = kelainan minimal	.818	.150	4.454
N of Valid Cases	36		



Lampiran 9

Hasil analisis statistik kadar albumin pada SNKM dan SNBKM

Ranks

	Biopsi	N	Mean Rank	Sum of Ranks
Albumin	kelainan minimal	10	20.55	205.50
	bukan kelainan minimal	26	17.71	460.50
	Total	36		

Test Statistics^a

	Albumin
Mann-Whitney U	109.500
Wilcoxon W	460.500
Z	-.727
Asymp. Sig. (2-tailed)	.467
Exact Sig. [2*(1-tailed Sig.)]	.475 ^b

a. Grouping Variable: Biopsi

b. Not corrected for ties.



Lampiran 10

Hasil analisis statistik distribusi berat edema pada SNKM dan SNBKM

Edema * Biopsi Crosstabulation

			Biopsi		Total
			kelainan minimal	bukan kelainan minimal	
Edema ringan	Count	4	7	11	
	Expected Count	3.1	7.9	11.0	
	% within Biopsi	40.0%	26.9%	30.6%	
sedang	Count	5	17	22	
	Expected Count	6.1	15.9	22.0	
	% within Biopsi	50.0%	65.4%	61.1%	
berat	Count	1	2	3	
	Expected Count	.8	2.2	3.0	
	% within Biopsi	10.0%	7.7%	8.3%	
Total	Count	10	26	36	
	Expected Count	10.0	26.0	36.0	
	% within Biopsi	100.0%	100.0%	100.0%	

Chi-Square Tests

	Value	df	Asymptotic Significance (2-sided)
Pearson Chi-Square	.730 ^a	2	.694
Likelihood Ratio	.719	2	.698
N of Valid Cases	36		

a. 3 cells (50.0%) have expected count less than 5. The minimum expected count is .83.



Risk Estimate

	Value
Odds Ratio for Edema (ringan / sedang)	^a

a. Risk Estimate statistics cannot be computed. They are only computed for a 2*2 table without empty cells.

Test Statistics^a

		Edema
Most Extreme Differences	Absolute	.131
	Positive	.023
	Negative	-.131
Kolmogorov-Smirnov Z		.351
Asymp. Sig. (2-tailed)		1.000

a. Grouping Variable: Biopsi



Lampiran 11

Hasil analisis statistik kadar kolesterol pada SNKM dan SNBKM

Ranks

	Biopsi	N	Mean Rank	Sum of Ranks
Kolesterol	kelainan minimal	10	16.85	168.50
	bukan kelainan minimal	26	19.13	497.50
	Total	36		

Test Statistics^a

	Kolestero 1
Mann-Whitney U	113.500
Wilcoxon W	168.500
Z	-.583
Asymp. Sig. (2-tailed)	.560
Exact Sig. [2*(1-tailed Sig.)]	.566 ^b

a. Grouping Variable: Biopsi

b. Not corrected for ties.



Lampiran 12

Hasil analisis statistik distribusi hematuria pada SNKM dan SNBKM

Hematuria * Biopsi Crosstabulation

			Biopsi		Total
			SNKM	SNBKM	
Hematuria	Ya	Count	3	20	23
		Expected Count	6.4	16.6	23.0
		% of Total	8.3%	55.6%	63.9%
Tidak	Ya	Count	7	6	13
		Expected Count	3.6	9.4	13.0
		% of Total	19.4%	16.7%	36.1%
Total		Count	10	26	36
		Expected Count	10.0	26.0	36.0
		% of Total	27.8%	72.2%	100.0%

Chi-Square Tests

	Value	df	Asymptotic Significance (2-sided)	Exact Sig. (2- sided)	Exact Sig. (1- sided)
Pearson Chi-Square	6.893 ^a	1	.009		
Continuity Correction ^b	5.009	1	.025		
Likelihood Ratio	6.784	1	.009		
Fisher's Exact Test				.018	.013
Linear-by-Linear Association	6.701	1	.010		
N of Valid Cases	36				

a. 1 cells (25.0%) have expected count less than 5. The minimum expected

count is

3.61. Continuity Correction is computed only for a 2x2 table



Risk Estimate

	Value	95% Confidence Interval	
		Lower	Upper
Odds Ratio for Hematuria (Ya / Tidak)	7.778	1.522	39.754
For cohort Biopsi = Bukan Kelainan Minimal	1.884	1.026	3.461
For cohort Biopsi = Kelainan Minimal	.242	.075	.780
N of Valid Cases	36		



Lampiran 13

Hasil analisis kadar kreatinin pada SNKM dan SNBKM

Ranks

	Biopsi	N	Mean Rank	Sum of Ranks
Kreatinin	kelainan minimal	10	16.55	165.50
	bukan kelainan minimal	26	19.25	500.50
	Total	36		

Test Statistics^a

	Kreatinin n
Mann-Whitney U	110.500
Wilcoxon W	165.500
Z	-.689
Asymp. Sig. (2-tailed)	.491
Exact Sig. [2*(1-tailed Sig.)]	.497 ^b

a. Grouping Variable: Biopsi

b. Not corrected for ties.



Lampiran 14

Hasil analisis statistik kadar ureum pada SNKM dan SNBKM

Ranks

	Biopsi	N	Mean Rank	Sum of Ranks
Ureum	kelainan minimal	10	14.30	143.00
	bukan kelainan minimal	26	20.12	523.00
	Total	36		

Test Statistics^a

	Ureum
Mann-Whitney U	88.000
Wilcoxon W	143.000
Z	-1.485
Asymp. Sig. (2-tailed)	.138
Exact Sig. [2*(1-tailed Sig.)]	.145 ^b

a. Grouping Variable: Biopsi

b. Not corrected for ties.



Lampiran 15

Hasil analisis statistik regresi ganda logistik pada SNKM dan SNBKM

Omnibus Tests of Model Coefficients

		Chi-square	df	Sig.
Step 1	Step	10.325	2	.006
	Block	10.325	2	.006
	Model	10.325	2	.006

Model Summary

Step	-2 Log likelihood	Cox & Snell R Square	Nagelkerke R Square
1	32.216 ^a	.249	.360

a. Estimation terminated at iteration number 5 because parameter estimates changed by less than ,001.

Hosmer and Lemeshow Test

Step	Chi-square	df	Sig.
1	2.561	2	.278

Contingency Table for Hosmer and Lemeshow Test

		Biopsi = SNKM		Biopsi = SNBKM		Total
		Observed	Expected	Observed	Expected	
Step 1	1	14	13.349	0	.651	14
	2	1	1.651	1	.349	2
	3	6	6.651	3	2.349	9
	4	5	4.349	6	6.651	11



Variables in the Equation

	B	S.E.	Wald	df	Sig.	Exp(B)	95% C.I. for EXP(B)	
							Lower	Upper
Step 1 ^a Hipertensi(1)	1.980	1.181	2.809	1	.094	7.239	.715	73.289
Hematuria(1)	1.466	.897	2.669	1	.102	4.331	.746	25.134
Constant	-3.020	1.087	7.724	1	.005	.049		

a. Variable(s) entered on step 1: Hipertensi, Hematuria.

